Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05159388 · ClinicalTrials.gov registry record · Phase 1
A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody) in Patients With Solid Tumors
A Phase 1 study, sponsored by Servier Bio-Innovation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT05159388 is a Phase 1 study that was terminated before completion, run by Servier Bio-Innovation. The registered enrollment target is 46 participants.
The verdict
NCT05159388, a Phase 1 study, was terminated before completion, sponsored by Servier Bio-Innovation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
This is a first-in-human (FIH), phase 1/2, multi center, open-label, dose escalation and cohort expansion study designed to determine the safety and tolerability of PRS-344/S095012 in patients with advanced and/or metastatic solid tumors.
Interventions
- DRUG PRS-344/S095012
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2021-09-08 |
| Est. Completion | 2025-04-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05159388
The ClinicalTrials.gov registry entry for NCT05159388 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Servier Bio-Innovation, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PRS-344/S095012 is the first listed.
NCT05159388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05159388 about?
NCT05159388 is a clinical study titled "A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody) in Patients With Solid Tumors". This is a first-in-human (FIH), phase 1/2, multi center, open-label, dose escalation and cohort expansion study designed to determine the safety and tolerability of PRS-344/S095012 in patients with advanced and/or metastatic solid tumors.
What is the current status of trial NCT05159388?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2021-09-08. Estimated completion is 2025-04-01.
What interventions are being tested in trial NCT05159388?
The interventions under investigation include: PRS-344/S095012 (DRUG).
Who is sponsoring clinical trial NCT05159388?
This trial is sponsored by Servier Bio-Innovation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.